Sanofi-Aventis sues Novopharm for patent infringement in Canada
Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited has obtained marketing approval in Canada for a product claiming to be generic enoxaparin.
Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®.
Sanofi-aventis will vigorously defend its legal rights with respect to this patent.
Most read news
Other news from the department politics & laws
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.